Risk of Metabolic Adaptation After Weight Loss
Biomarkers of Increased Risk of Developing Metabolic Adaptation to Weight Loss
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lisa L Morselli, MD PhD
- Phone Number: 414-955-6710
- Email: lmorselli@mcw.edu
Study Contact Backup
- Name: Roland James
- Phone Number: 414-955-4992
- Email: rjames@mcw.edu
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
BMI > or = 30 any ethnicity
Exclusion Criteria:
weight > or = 400 lbs.
diabetes (type 2 or type 1)
hypertension
heart disease
kidney disease
liver disease
active cancer
post solid organ or bone marrow transplant
HIV/AIDS
pregnancy
breastfeeding
current smoker
current recreational drug use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: lifestyle intervention
Participants will be enrolled in a weight loss program based on lifestyle changes.
They will be given a 6-month subscription to a calorie-reduced meal replacement program that also offers lifestyle coaching.
|
participants will be enrolled in a medical weight loss program and will be given a 6 month subscription to a calorie-reduced meal replacement program, in addition to lifestyle advice.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in measured and predicted resting metabolic rate during and after weight loss
Time Frame: 18 months
|
resting metabolic rate will be measured by indirect calorimetry every 2 months for 6 months, then every 6 months for an additional 12 month.
Predicted resting metabolic rate will be calculated with a mathematical formula at the same time points
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in circulating leptin during and after weight loss
Time Frame: 18 months
|
blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
|
18 months
|
|
change in circulating thyroid hormones during and after weight loss
Time Frame: 18 months
|
blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
|
18 months
|
|
change in circulating GLP-1 during and after weight loss
Time Frame: 18 months
|
blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
|
18 months
|
|
change in circulating PYY during and after weight loss
Time Frame: 18 months
|
blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
|
18 months
|
|
change in circulating AgRP during and after weight loss
Time Frame: 18 months
|
blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
|
18 months
|
|
change in 24h urine catecholamines during and after weight loss
Time Frame: 18 months
|
urine will be assayed for these hormones every 2 months for 6 months, then every 6 months for an additional 12 months
|
18 months
|
|
change in heart rate variability during and after weight loss
Time Frame: 18 months
|
blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lisa L Morselli, MD PhD, Medical College of Wisconsin
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Overnutrition
- Body Weight
- Body Weight Changes
- Overweight
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Weight Loss
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anticonvulsants
- Appetite Depressants
- Anti-Obesity Agents
- Central Nervous System Stimulants
- Sympathomimetics
- Topiramate
- Phentermine
Other Study ID Numbers
Other Study ID Numbers
- PRO00039217
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.